The Latest Issue of ONCOLife Is Now Live – Follow the Cutting Edge of Oncology Innovation

The new issue of ONCOLife, one of the leading oncology magazines for healthcare professionals, is now available — and it brings together some of the most forward-thinking innovations and expert insights shaping the future of cancer care. With a strong focus on targeted therapies, novel immunotherapies, and the integration of AI in drug discovery, this issue offers a comprehensive view into the next generation of oncology breakthroughs.

Targeting the 'Don’t Eat Me' Signal

One of the standout features in this issue is an exclusive interview with Dr. Raphaël Rousseau, Chief Medical Officer at Pheast Therapeutics, who discusses the transformative potential of macrophage checkpoint inhibitors. By targeting the CD24 "don't eat me" signal, these therapies aim to activate macrophages to recognize and destroy cancer cells more effectively—offering new hope in challenging cancers like ovarian and triple-negative breast cancer. Dr. Rousseau shares promising preclinical and early clinical findings, as well as insights on biomarker selection and combination strategies.

HPV16+ Cancers: A Targeted Immunotherapy

Another highlight is a conversation with Frank Bedu-Addo, President and CEO of PDS Biotech, who introduces Versamune® HPV, an investigational targeted immunotherapy developed to combat HPV16-driven tumors. Data from the VERSATILE-002 Phase 2 trial are nothing short of remarkable: a median overall survival of 30 months in recurrent/metastatic HPV16-positive head and neck cancer. This promising approach represents a major step forward in the fight against HPV-associated malignancies.

Microneedle Patch for Skin Cancer

Innovative, patient-friendly treatment options are also under the spotlight. In an exclusive interview, Dr. Raza Bokhari, CEO of Medicus Pharma, unveils SkinJect, a cellulose-based microneedle patch designed to deliver doxorubicin directly into basal cell carcinoma lesions. The goal: to offer an effective, non-invasive, and cosmetically favorable alternative to traditional surgical treatments.

Darolutamide in Prostate Cancer and the ARANOTE Trial

Prostate cancer also takes center stage with insights from Dr. Iris Kuss, VP and Global Development Lead Oncology at Bayer. She details the ARANOTE Phase III trial, which showed that darolutamide in combination with ADT reduces the risk of progression or death by 46% in metastatic hormone-sensitive prostate cancer, while maintaining a strong safety profile.

Redefining Breast Cancer Care with ADCs

Dr. Elvina Almuradova shares encouraging results from the TROPION-Breast01 trial, which introduces datopotamab deruxtecan (Dato-DXd) as a new treatment standard for HR+/HER2– metastatic breast cancer patients resistant to endocrine therapy. The trial demonstrated improved progression-free survival and reduced toxicity compared to chemotherapy.

AI in Drug Discovery: From Concept to Cure

In the digital innovation realm, Dr. Chris Foley from bioXcelerate discusses how artificial intelligence is accelerating early-stage drug discovery. With platforms like Ant Map and Switch Step, his team is tackling persistent challenges like missing data, while dramatically shortening time to actionable insights.

Expanding Clinical Trial Capacity

Finally, Dr. Neal Shore discusses how the Carolina Urologic Research Center (CURC)’s integration with the START global network is reshaping genitourinary oncology research. By leveraging advanced imaging, novel trial endpoints, and precision biomarkers, CURC is now a leader in first-in-human clinical studies.